News & Events
Cognitive rehabilitation in MS
Computer-aided cognitive rehabilitation can slow down cognitive impairment in MS patients
Avoiding post-partum MS worsening
French study supports the idea of avoiding delays after pregnancy before starting natalizumab therapy
Trigeminal neuralgia and fampridine: further contraindication
Fampridine must be used with caution in people with a history of MS-related trigeminal neuralgia
New treatment for fatigue
Researchers find that Alfacalcidol is a safe and effective treatment for fatigue
Phase one of European Register for MS completed
The register aims to address the recognised lack of relevant MS data at European level
Treat Me Right campaign changes UK guidelines
The UK MS Society’s campaign calls for the right treatment at the right time
Middle East volunteers trained in MS counselling
Volunteers from MS organisations in Lebanon, Egypt and Jordan took part in a three-day training course
2014 McDonald Fellowships announced
This year’s McDonald Fellowships went to researchers from Bangladesh, Hungary, Iran and Yemen
More Du Pré Grants for 2014 announced
The second wave of 2014 grants includes scientists from Iran, Italy, Romania and Russia
New type of interferon has fewer side effects
Pegylated interferon lasts longer, so needs to be taken less often, with fewer side effects
Pros and cons of alemtuzumab
Alemtuzumab has been approved in Europe, Canada, Australia, and Latin America
Better test for risk of PML infection in Natalizumab patients
The new test measures the risk of PML infection in people being treated with Natalizumab